Results of phase III trial of Olumiant + Veklury in COVID-19 published in NEJM.- Eli Lilly and Incyte

Eli Lilly and Incyte announced that The New England Journal of Medicine has published peer-reviewed results from the Adaptive COVID-19 Treatment Trial (ACTT-2) of patients treated with Olumiant (baricitinib) in combination with Veklury (remdesivir) for treating COVID-19. The Phase III study included 1,033 patients from 67 trial sites in eight countries. These results support the emergency use authorization (EUA) issued by the FDA on Nov. 19 for baricitinib in combination with remdesivir in hospitalized patients with COVID-19 requiring supplemental oxygen. The paper shows that baricitinib plus remdesivir was superior to remdesivir alone in reducing recovery time and accelerating improvement in clinical status among patients with Covid-19, notably among those receiving high-flow oxygen or noninvasive ventilation. The combination was associated with fewer serious adverse events. See: "Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19." Andre C. Kalil et al. NEJM December 11, 2020 DOI: 10.1056/NEJMoa2031994